Metabolic dysfunction-associated fatty liver disease

There are 86 papers on metabolic dysfunction-associated fatty liver disease in aging research: 7 trials and 49 observational studies in people, 10 in animals, 1 in cells, 18 reviews. The newest story, Nov 9, 2026: “Gene variants linked to higher odds of fatty liver disease”.

Disease

86 papers study it22 more mention it58 findings

12 new papers in 30 daysSee all 108 papers on metabolic dysfunction-associated fatty liver disease

At a glance

Human studies link metabolic dysfunction-associated fatty liver disease with higher mortality, incident chronic kidney disease and physical disability. They also associate it with PhenoAge acceleration and a retinal microvascular aging index; in patients with osteopenia, it is linked with worse physical function and higher oxidative stress.

58 findings in 34 papers from 2022 to 2026, 9 of them since May 2026

“Young adults with MAFLD had a 1.30 (95% CIs 1.26-1.35) and 1.40 (1.23-1.59) times higher prevalence of low- and high-risk adenomas, respectively, compared to those without MAFLD.”
Metabolic-associated fatty liver disease is associated with colorectal adenomas in young and older Korean adultsLiver international : official journal of the International Association for the Study of the Liver2023doi:10.1111/liv.15738
  • Human trial7
  • Humans49
  • Animals10
  • Cells1
  • In silico1

Interventions

4

Metformin + naringin

downin rats1

1 study
  1. Metformin + naringin decreases metabolic dysfunction-associated fatty liver disease in high-fructose diet-fed rats.

    “Combined Met + NAR improves systemic, structural, and molecular alterations in experimental MAFLD.”

    Animalsin high-fructose diet-fed ratsliver40 daysmales

    Metformin plus naringin: a new optional treatment for metabolic dysfunction associated with fatty liver disease in a rat experimental model of high-fructose consumption

    European journal of pharmacology

More on Metformin + naringin

Dietary modification

downin humans1

1 study
  1. Dietary modification prevents metabolic dysfunction-associated fatty liver disease in humans.

    “The recommended dietary strategies emphasize adherence to a balanced diet with controlled energy intake and personalized nutritional interventions, such as calorie restriction, high-protein, or low-carbohydrate diets.”

    Review

    The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus

    Metabolism: clinical and experimental

More on Dietary modification

Physical activity

downin humans1

1 study
  1. Physical activity prevents metabolic dysfunction-associated fatty liver disease in humans.

    “Increasing physical activity and reducing sedentary behavior can prevent MAFLD”

    Review

    Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective

    Hepatology international

More on Physical activity

Aerobic exercise

downin humans1

1 study
  1. Aerobic exercise decreases metabolic dysfunction-associated fatty liver disease in MAFLD (150-240 min/week).

    “strongest evidence in MAFLD supporting regular structured moderate-vigorous aerobic exercise for 150-240 min/week.”

    Reviewin MAFLD150-240 min/week

    Lifestyle intervention for metabolic dysfunction-associated fatty liver disease: a 24-h integrated behavior perspective

    Hepatology international

More on Aerobic exercise

Effects

3

Mitochondrial fission and fusion

downin humans1

1 study
  1. Metabolic dysfunction-associated fatty liver disease is linked with worse mitochondrial fission and fusion in patients with osteopenia.

    “peripheral blood macrophages in patients with MAFLD with more unbalanced mitochondrial dynamics of macrophages, more weakened mitochondrial respiratory capacity, and greater mitochondrial microstructure damage”

    Humansin patients with osteopeniamacrophagesn = 107

    The Imbalance of Mitochondrial Homeostasis of Peripheral Blood-Derived Macrophages Mediated by MAFLD May Impair the Walking Ability of Elderly Patients with Osteopenia

    Oxidative medicine and cellular longevity

More on Mitochondrial fission and fusion

Oxidative stress and ROS signaling

upin humans1

1 study
  1. Metabolic dysfunction-associated fatty liver disease is linked with higher oxidative stress and ROS signaling in patients with osteopenia.

    “mitochondrial reactive oxygen species (mtROS) in peripheral blood of OPe patients with MAFLD was significantly higher than those without”

    Humansin patients with osteopeniaperipheral bloodn = 107

    The Imbalance of Mitochondrial Homeostasis of Peripheral Blood-Derived Macrophages Mediated by MAFLD May Impair the Walking Ability of Elderly Patients with Osteopenia

    Oxidative medicine and cellular longevity

More on Oxidative stress and ROS signaling

Physical function

downin humans1

1 study
  1. Metabolic dysfunction-associated fatty liver disease is linked with worse physical function in patients with osteopenia (P = 0.012 (6MWD), P = 0.0029 (SPPB)).

    “six-minute walking distance (P = 0.012) and short physical performance battery (SPPB) score (P = 0.0029) of the elderly OPe patients with MAFLD are worse than those in OPe patients without MAFLD”

    Humansin patients with osteopenian = 107

    The Imbalance of Mitochondrial Homeostasis of Peripheral Blood-Derived Macrophages Mediated by MAFLD May Impair the Walking Ability of Elderly Patients with Osteopenia

    Oxidative medicine and cellular longevity

Upstream

2

dysregulated cholesterol flux

mediatesin reviews1

1 study
  1. dysregulated cholesterol flux mediates metabolic dysfunction-associated fatty liver disease.

    “dysregulation of cholesterol flux underpins pathogenesis in atherosclerosis, metabolic dysfunction-associated fatty liver disease (MAFLD), neurodegenerative disorders, and oncogenesis”

    Review

    Cholesterol metabolism: molecular mechanisms, biological functions, diseases, and therapeutic targets

    Molecular biomedicine

Early adulthood adiposity

mediatesin humans1

1 study
  1. Early adulthood adiposity is linked with metabolic dysfunction-associated fatty liver disease in humans.

    “Early adulthood adiposity partially mediated this association.”

    HumansPartial mediation of the association between age at menarche and MAFLD; adiposity around age 25femalesn = 46,873

    Age at menarche and metabolic dysfunction-associated fatty liver disease: Evidence from a large population-based epidemiological study in Southwest China

    Preventive medicine

Associations

44

Osteoporosis

upin humans2

2 studies
  1. Metabolic dysfunction-associated fatty liver disease is associated with osteoporosis in humans.

    “the increased risk of osteoporosis exists only in MAFLD patients with lean/normal weight.”

    HumansBMI <23 kg/m2; compared with subjects without metabolic dysfunction-associated fatty liver disease

    Increased risk of osteoporosis in lean/normal weight metabolic dysfunction‐associated fatty liver disease patients

    Advances in digestive medicine

  2. Metabolic dysfunction-associated fatty liver disease is associated with osteoporosis in humans.

    “There is growing evidence that supports a connection between MAFLD and osteoporosis.”

    Review

    The hidden fragility: Unmasking the systematic link between lean metabolic dysfunction‐associated fatty liver disease and osteoporosis

    Advances in digestive medicine

More on Osteoporosis

Snoring

upin humans2OR 1.2–1.59

2 studies
  1. Metabolic dysfunction-associated fatty liver disease is linked with a higher risk of snoring in humans (OR: 1.2, 95% CI: 1.02-1.5, P = 0.02).

    “snoring (OR: 1.2, 95% CI: 1.02-1.5, P = 0.02)”

    Humans

    Metabolic dysfunction-associated fatty liver disease increases the risk of sleep abnormalities: an analysis of the National Health and Nutrition Examination Survey 2017-2020

    European journal of gastroenterology & hepatology

  2. Snoring is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans after full adjustments including obesity (OR 1.59 (95% CI 1.33, 1.91)).

    “snoring, and daytime napping for over 30 minutes significantly associated with an increased risk of MAFLD, with odds ratios (OR) of 1.37 (95% CI 1.10, 1.70), 1.59 (95% CI 1.33, 1.91)”

    Humansafter full adjustments including obesity

    Sleep Factors in Relation to Metabolic Dysfunction-Associated Fatty Liver Disease in Middle-Aged and Elderly Chinese

    The Journal of clinical endocrinology and metabolism

Mortality

upin humans2HR 1.26

2 studies
  1. Metabolic dysfunction-associated fatty liver disease is linked with a higher risk of mortality in humans (HR 1.26, 95% CI 1.00-1.59).

    “MAFLD increased the risk of all-cause mortality (hazard ratio [HR] 1.26, 95% confidence interval [CI] 1.00-1.59).”

    Humans15.7 yearsn = 6,543

    Impact of steatotic liver disease subtypes, sarcopenia, and fibrosis on all-cause and cause-specific mortality: a 15.7-year cohort study

    BMC gastroenterology

  2. Metabolic dysfunction-associated fatty liver disease is linked with a higher risk of mortality in humans (aHR 1.18, 95% CI 1.04-1.33).

    “both MAFLD and MASLD were associated with increased risk of all-cause mortality (adjusted hazard ratio [aHR] 1.18, 95% CI 1.04-1.33 and 1.19, 1.06-1.34, respectively)”

    Humansmedian follow-up of 26.9 yearsn = 7,519

    Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults

    Liver international : official journal of the International Association for the Study of the Liver

PhenoAgeAccel

upin humans1OR 1.66

1 study
  1. PhenoAgeAccel predicts metabolic dysfunction-associated fatty liver disease in humans (discrimination of MAFLD) (AUC = 0.622).

    “PhenoAgeAccel demonstrated better discriminative ability (AUC = 0.622) than traditional fibrosis scores (FIB-4, NFS, BARD), with a high negative predictive value (88.8%).”

    Humansdiscrimination of MAFLD

    Phenotypic age acceleration: a novel biomarker associated with increased risk of metabolic dysfunction-associated fatty liver disease

    Nutrition & metabolism

  2. PhenoAgeAccel is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (case-control analysis, multivariable adjustment) (OR 1.66, 95% CI: 1.56-1.77).

    “In the case-control analysis, each 5-year increase in PhenoAgeAccel was associated with 66% higher odds of MAFLD after multivariable adjustment (OR = 1.66, 95% CI: 1.56-1.77).”

    Humanscase-control analysis, multivariable adjustmenteach 5-year increase

    Phenotypic age acceleration: a novel biomarker associated with increased risk of metabolic dysfunction-associated fatty liver disease

    Nutrition & metabolism

More on PhenoAgeAccel

TyG-BMI

upin humans1OR 3.7

1 study
  1. TyG-BMI predicts metabolic dysfunction-associated fatty liver disease in humans (screening MAFLD) (AUC 0.81, P < 0.001).

    “The area under the ROC curve (AUC) for TyG-BMI was 0.81, and its predictive performance was significantly superior to that of the other parameters”

    Humansscreening MAFLDn = 1,592

    The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study

    Frontiers in nutrition

  2. TyG-BMI is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (multivariable logistic regression) (OR = 3.7, 95% CI: 3.05-4.48).

    “TyG-BMI demonstrating the strongest association (OR = 3.7, 95% CI: 3.05-4.48).”

    Humansmultivariable logistic regressionn = 1,592

    The development and evaluation of nine non-conventional lipid parameters for metabolic dysfunction-associated fatty liver disease in Chinese medical health examination adults: a single-center retrospective study

    Frontiers in nutrition

More on TyG-BMI

APOB

upin humans1OR 3.2

1 study
  1. APOB is linked with a higher risk of metabolic dysfunction-associated fatty liver disease in humans (Heterozygous APOB pLoF carriers in HRN; validated across all cohorts) (OR=3.2).

    “and elevated risk for MAFLD (OR=3.2), which validated across all cohorts.”

    HumansHeterozygous APOB pLoF carriers in HRN; validated across all cohortslivern = 449

    Gene variants linked to higher odds of fatty liver disease

    AHA Scientific Sessions 2026 abstract

More on APOB

Skeletal muscle mass to visceral fat area ratio

downin humans1

1 study
  1. Skeletal muscle mass to visceral fat area ratio is associated with metabolic dysfunction-associated fatty liver disease in humans (routine health examination population; prevalent disease).

    “SVR showed a strong inverse association with MAFLD (OR = 0.383, 95% CI: 0.368–0.399).”

    Humansroutine health examination population; prevalent diseasen = 11,977

    Association between skeletal muscle mass-to-visceral fat area ratio and metabolic dysfunction-associated fatty liver disease in a large health examination cohort: a cross-sectional study

    Frontiers in medicine

More on Skeletal muscle mass to visceral fat area ratio

CALLY index

downin humans1OR 0.57

1 study
  1. CALLY index is associated with metabolic dysfunction-associated fatty liver disease in humans (prevalent MAFLD) (OR 0.57, 95% CI 0.52–0.64).

    “ln(CALLY) was inversely associated with MAFLD (OR = 0.57, 95% CI: 0.52-0.64, p < 0.001).”

    Humansprevalent MAFLDnatural-log transformedn = 3,841

    Inverse Association of the Life's Crucial 9 Score With MAFLD: An Exploratory Mediation Analysis of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index

    International journal of endocrinology

More on CALLY index

Life's Crucial 9

downin humans1OR 0.51

1 study
  1. Life's Crucial 9 is associated with metabolic dysfunction-associated fatty liver disease in humans (prevalent MAFLD) (OR 0.51 per 10-point increase, 95% CI 0.47–0.56).

    “every 10-point increase in the LC9 score was associated with lower odds of MAFLD”

    Humansprevalent MAFLDper 10-point increasen = 3,841

    Inverse Association of the Life's Crucial 9 Score With MAFLD: An Exploratory Mediation Analysis of the C-Reactive Protein-Albumin-Lymphocyte (CALLY) Index

    International journal of endocrinology

More on Life's Crucial 9

Incident chronic kidney disease

upin humans1HR 1.26

1 study
  1. Metabolic dysfunction-associated fatty liver disease is associated with incident chronic kidney disease in humans (CKD defined as eGFR < 60 ml/min/1.73 m 2) (26% increased risk; HR 1.26, 95% CI 1.11–1.43).

    “MAFLD was associated with a 26% increased risk of incident CKD (hazard ratio: 1.26, 95% CI: 1.11–1.43; P < 0.001).”

    HumansCKD defined as eGFR < 60 ml/min/1.73 m 2kidneyMedian follow-up 15.4 years

    Metabolic dysfunction-associated fatty liver disease and long-term kidney function decline: a 16-year population-based cohort study

    Scientific reports

More on Incident chronic kidney disease

All 44

Trial sponsors

Funding

1 grant since 2022

Health and Medical Research FundHK$1.5M

How this record changed

  1. Summary written from the findings.

Latest

Dec 2025: 1Jan 2026: 9Feb 2026: 9Mar 2026: 12Apr 2026: 3May 2026: 1Jun 2026: 5Jul 2026: 0Aug 2026: 5Sep 2026: 3Oct 2026: 8Nov 2026: 662 papers in 12 months
AHA Scientific Sessions 2026 Abstract

Gene variants linked to higher odds of fatty liver disease

In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.

Genetic association · 402,437 peopleMechanisms
Autophagy

Protein change helps exercise trigger recycling in the liver

Experiments linked a chemical change in a cell-recycling protein to exercise-related improvements in insulin responses and liver fat metabolism.Experiments linked a chemical change in a cell-recycling protein to exercise-related improvements in insulin responses and liver fat metabolism.

Mouse study · 6 miceExercise

See all 108 papers on metabolic dysfunction-associated fatty liver disease